Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease
详细信息 查看全文
- 作者：Lenneke F.J. van Groningen1 ; 2 ; Lenneke.vanGroningen@radboudumc.nl" class="auth_mail" title="E-mail the corresponding author ; Aleida M. Liefferink1 ; Anton F.J. de Haan3 ; Nicolaas P.M. Schaap1 ; J. Peter Donnelly1 ; 2 ; Nicole M.A. Blijlevens1 ; 2 ; Walter J.F.M. van der Velden1 ; 2
- 关键词：Allogeneic stem cell transplantation ; Acute GVHD ; Steroid refractory ; Inolimomab ; Etanercept
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：January 2016
- 年：2016
- 卷：22
- 期：1
- 页码：179-182
- 全文大小：172 K
文摘
- •
Steroid-refractory aGVHD remains an important cause of morbidity and mortality after allogeneic stem cell transplantation.
- •
We examined a combination therapy with inolimomab and etanercept for patients with a steroid-refractory aGVHD.
- •
The combination of inolimomab and etanercept for steroid-refractory aGVHD failed to improve the dismal prognosis of severe steroid-refractory aGVHD.